Payment overview · 2025
General Payments
$612.34
6 reported records · 6 companies
Healthcare provider profile · identity verified
Suzanne Ransehousen, CRNP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner · HOCKESSIN, DE · NPI 1255323556
Verified facts
What the public records show
CMS Open Payments records show Suzanne Ransehousen, CRNP received $612.34 in general payments during 2025 across 6 reported records.
SUN PHARMACEUTICAL INDUSTRIES INC. accounted for 23.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 7 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Arexvy, Rexulti.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 165 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Arexvy by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Rexulti by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| SUN PHARMACEUTICAL INDUSTRIES INC. | Unresolved — no canonical attribution shown | $142.21 | 23.2% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $123.05 | 20.1% | 1 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $99.65 | 16.3% | 1 | 2025 |
| Cipher Pharmaceuticals US LLC | Unresolved — no canonical attribution shown | $99.12 | 16.2% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $88.22 | 14.4% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $60.09 | 9.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $612.34 | 6 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| DRIZALMA SPRINKLE Normalized: drizalma sprinkle |
Drug | SUN PHARMACEUTICAL INDUSTRIES INC. | $142.21 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $123.05 | 1 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $99.65 | 1 | 2025 |
Source payment records
|
|||||
| Natroba Normalized: natroba |
Drug | Cipher Pharmaceuticals US LLC | $99.12 | 1 | 2025 |
Source payment records
|
|||||
| Spinosad Normalized: spinosad |
Drug | Cipher Pharmaceuticals US LLC | $99.12 | 1 | 2025 |
Source payment records
|
|||||
| COBENFY Normalized: cobenfy |
Drug | E.R. Squibb & Sons, L.L.C. | $88.22 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $60.09 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| AREXVY arexvy |
2025 | Arexvy | 2024 | 13 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
165 | 26 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
13 | 13 |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 339 | 59 |
| Atorvastatin Calcium | Atorvastatin Calcium | 281 | 56 |
| Escitalopram Oxalate | Escitalopram Oxalate | 273 | 51 |
| Gabapentin | Gabapentin | 222 | 39 |
| Amlodipine Besylate | Amlodipine Besylate | 199 | 44 |
| Metoprolol Succinate | Metoprolol Succinate | 189 | 36 |
| Omeprazole | Omeprazole | 183 | 36 |
| Furosemide | Furosemide | 176 | 39 |
| Eliquis | Apixaban | 165 | 26 |
| Losartan Potassium | Losartan Potassium | 159 | 31 |
| Tamsulosin Hcl | Tamsulosin Hcl | 147 | 20 |
| Lisinopril | Lisinopril | 137 | 26 |
| Duloxetine Hcl | Duloxetine Hcl | 92 | 15 |
| Mirtazapine | Mirtazapine | 90 | 16 |
| Carvedilol | Carvedilol | 71 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 71 | 19 |
| Trulicity | Dulaglutide | 68 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 67 | 13 |
| Trazodone Hcl | Trazodone Hcl | 67 | 17 |
| Tramadol Hcl | Tramadol Hcl | 65 | 13 |
| Xarelto | Rivaroxaban | 65 | 11 |
| Metoprolol Tartrate | Metoprolol Tartrate | 64 | 16 |
| Lorazepam | Lorazepam | 62 | 20 |
| Amiodarone Hcl | Amiodarone Hcl | 59 | 11 |
| Alendronate Sodium | Alendronate Sodium | 56 | suppressed |
| Baclofen | Baclofen | 56 | suppressed |
| Potassium Chloride | Potassium Chloride | 53 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 52 | suppressed |
| Metformin Hcl | Metformin Hcl | 51 | 12 |
| Prednisone | Prednisone | 51 | 22 |
| Sertraline Hcl | Sertraline Hcl | 51 | suppressed |
| Januvia | Sitagliptin Phosphate | 50 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 47 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 45 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 41 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 41 | 27 |
| Allopurinol | Allopurinol | 39 | suppressed |
| Valsartan | Valsartan | 38 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 36 | suppressed |
| Bupropion Xl | Bupropion Hcl | 35 | suppressed |
| Nystatin | Nystatin | 35 | 17 |
| Diclofenac Sodium | Diclofenac Sodium | 34 | suppressed |
| Latanoprost | Latanoprost | 34 | suppressed |
| Simvastatin | Simvastatin | 34 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 33 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 32 | 14 |
| Spironolactone | Spironolactone | 32 | suppressed |
| Clonazepam | Clonazepam | 31 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 31 | suppressed |
| Alprazolam | Alprazolam | 30 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 30 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 30 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 30 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 28 | 17 |
| Famotidine | Famotidine | 28 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 28 | suppressed |
| Ketoconazole | Ketoconazole | 26 | 11 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 26 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 25 | suppressed |
| Amoxicillin | Amoxicillin | 25 | suppressed |
| Bumetanide | Bumetanide | 25 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 25 | 17 |
| Finasteride | Finasteride | 24 | suppressed |
| Ozempic | Semaglutide | 24 | suppressed |
| Atenolol | Atenolol | 23 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 23 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 23 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 23 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 23 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 22 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 22 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 21 | suppressed |
| Celecoxib | Celecoxib | 20 | suppressed |
| Budesonide | Budesonide | 19 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 19 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 19 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 19 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 18 | 12 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 18 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 18 | suppressed |
| Memantine Hcl | Memantine Hcl | 18 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 18 | suppressed |
| Glipizide Er | Glipizide | 17 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 17 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 16 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 16 | suppressed |
| Synthroid | Levothyroxine Sodium | 16 | suppressed |
| Azithromycin | Azithromycin | 15 | 11 |
| Buprenorphine | Buprenorphine | 15 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 15 | suppressed |
| Methimazole | Methimazole | 15 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 15 | suppressed |
| Verapamil Er | Verapamil Hcl | 15 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 14 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 14 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 14 | suppressed |
| Restasis | Cyclosporine | 14 | suppressed |
| Acetazolamide | Acetazolamide | 13 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 13 | 13 |
| Benazepril Hcl | Benazepril Hcl | 13 | suppressed |
| Cephalexin | Cephalexin | 13 | 11 |
| Colesevelam Hcl | Colesevelam Hcl | 13 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 13 | suppressed |
| Levofloxacin | Levofloxacin | 13 | suppressed |
| Meloxicam | Meloxicam | 13 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 13 | 11 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 13 | suppressed |
| Temazepam | Temazepam | 13 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 12 | suppressed |
| Cyclosporine | Cyclosporine | 12 | suppressed |
| Desmopressin Acetate | Desmopressin Acetate | 12 | suppressed |
| Estradiol | Estradiol | 12 | suppressed |
| Ezetimibe | Ezetimibe | 12 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 12 | suppressed |
| Felodipine Er | Felodipine | 12 | suppressed |
| Levetiracetam | Levetiracetam | 12 | suppressed |
| Myrbetriq | Mirabegron | 12 | suppressed |
| Oxycontin | Oxycodone Hcl | 12 | suppressed |
| Pregabalin | Pregabalin | 12 | suppressed |
| Rexulti | Brexpiprazole | 12 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 12 | suppressed |
| Admelog Solostar | Insulin Lispro | 11 | suppressed |
| Lansoprazole | Lansoprazole | 11 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Minoxidil | Minoxidil | 11 | suppressed |
| Primidone | Primidone | 11 | suppressed |
| Telmisartan | Telmisartan | 11 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $612.34 · 6 records | SUN PHARMACEUTICAL INDUSTRIES INC. | AREXVY, AUSTEDO XR, COBENFY, DRIZALMA SPRINKLE, Natroba, REXULTI, Spinosad | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Arexvy play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with E.R. Squibb & Sons, L.L.C.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error